Les malalties pulmonars intersticials (MPI) s\u00f3n un grup heterogeni de malalties rares que produeixen una cicatritzaci\u00f3 progressiva als pulmons que acaba resultant en la mort del pacient. Les opcions terap\u00e8utiques disponibles no s\u00f3n efectives en tots els pacients, ja que la resposta al tractament \u00e9s molt variable. A m\u00e9s, establir un diagn\u00f2stic correcte \u00e9s dif\u00edcil en la majoria dels casos, especialment quan la malaltia ha avan\u00e7at massa com per tolerar procediments invasius. Amb el projecte<\/strong> PRECISION-ILD<\/strong>, l’equip de la Dra Molina treballar\u00e0 per, en primer lloc, millorar la superviv\u00e8ncia i la qualitat assistencial dels pacients amb MPIs i, en segon lloc, augmentar l’efici\u00e8ncia dels recursos sanitaris. Avui, les MPIs tenen un impacte estimat de 1.550 milions d’euros anuals en el sistema nacional de salut, xifra que es podria reduir significativament amb un avan\u00e7ament del diagn\u00f2stic.<\/p>\n S\u2019utilitzaran t\u00e8cniques d\u2019interpretaci\u00f3 de dades basades en la intel\u00b7lig\u00e8ncia artificial i el modelatge computacional per analitzar i integrar les caracter\u00edstiques moleculars, gen\u00f2miques, morfol\u00f2giques i ambientals de la malaltia en els pacients de les cohorts de MPIs ja existents a nivell estatal, que seran ampliades, actualitzades i unificades gr\u00e0cies a la col\u00b7laboraci\u00f3 amb 20 centres de 12 regions del pa\u00eds, incloent l\u2019IIB Alberto Sols-IDiPAZ, Hospital La Princesa Madrid, Hospital Universitario de Canarias, Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC) e ITER, Barcelona Supercomputing Center (BSC), Hospital Son Espases-IdISBa (Mallorca), Hospital Royo Vilanova i Universidad de Zaragoza, Universidad de Valencia, HUCA-Universidad de Oviedo, Hospital Valdecillas-IDIVAL (Santander), Hospital Alvaro Cunqueiro de Vigo, Hospital San Pedro Alc\u00e1ntara C\u00e1ceres i Hospital Virgen del Rocio Sevilla. Tal com explica la Dra Molina<\/strong>, \u201cAquest \u00e9s el primer estudi en malalties pulmonars intersticials que aplega investigadors de tot el pa\u00eds i que donar\u00e0 resposta a necessitats diagn\u00f2stiques i terap\u00e8utiques de pacients d\u2019arreu de l\u2019Estat\u201d.<\/em><\/p>\n <\/p>\n Projecte IMPaCT_VUSCan: abordar casos no resolts en c\u00e0ncer hereditari<\/strong><\/p>\n Per altra banda, l’equip de la Dra L\u00e1zaro treballar\u00e0 en la millora de les proves gen\u00e8tiques per al diagn\u00f2stic de c\u00e0ncer hereditari. Avui dia, el repte m\u00e9s important associat a l’\u00fas de tecnologies de seq\u00fcenciaci\u00f3 d’alt rendiment \u00e9s la identificaci\u00f3 de variants de significat desconegut (VUS), que no tenen aplicabilitat cl\u00ednica. La iniciativa IMPaCT-Gen\u00f3mica ha desenvolupat la plataforma b\u00e0sica per avaluar casos no resolts amb sospita de malaltia gen\u00e8tica, incloent el c\u00e0ncer hereditari, per\u00f2 tamb\u00e9 es preveu que apareguin moltes m\u00e9s VUS. Amb aix\u00f2 es requeriran m\u00e9s estudis per tal d\u2019arribar a una classificaci\u00f3 definitiva d\u2019aquestes variants i aconseguir el diagn\u00f2stic gen\u00e8tic que aquestes fam\u00edlies necessiten. L’objectiu principal del projecte<\/strong> IMPaCT_VUSCan<\/strong> \u00e9s implementar una estrat\u00e8gia integral de gen\u00f2mica funcional que permeti trobar una aplicabilitat cl\u00ednica a aquests VUS, ajudant aix\u00ed a resoldre un major nombre de casos amb possible predisposici\u00f3 al c\u00e0ncer. Per aconseguir-ho, els investigadors utilitzaran la intel\u00b7lig\u00e8ncia artificial i t\u00e8cniques multi\u00f2miques.<\/p>\n Al mateix temps, el projecte proporcionar\u00e0 un protocol validat de caracteritzaci\u00f3 gen\u00e8tica del c\u00e0ncer hereditari que facilitar\u00e0 la presa de decisions cl\u00edniques a tot l’estat gr\u00e0cies a la participaci\u00f3 d\u2019altres centres en el projecte: IIB Sant Pau (Barcelona), CNIO, IdiSSC, HU-La Paz i IdiPaz (Madrid), NB-IdiSNA (Navarra), Fundaci\u00f3n P\u00fablica Galega de Medicina Xen\u00f3mica (FPGMX, Galicia), Fundaci\u00f3n para el Fomento de la Investigaci\u00f3n Sanitaria y Biom\u00e9dica de la Comunitat Valenciana (Fisabio-DS, Elche), Fundaci\u00f3n Instituto Investigaci\u00f3n Sanitaria Islas Baleares (IDISBA, Palma de Mallorca). Tal com explica la Dra Lazaro<\/strong>, “l’aplicaci\u00f3 de la gen\u00e8tica humana i la gen\u00f2mica a l’atenci\u00f3 sanit\u00e0ria ha millorat la salut dels pacients amb c\u00e0ncer hereditari, per\u00f2 encara hi ha molts reptes que la investigaci\u00f3 biom\u00e8dica ha de superar”<\/em>.<\/p>\n <\/p>\n Projectes finan\u00e7ats per:<\/p>\n Refer\u00e8ncia: PMP22\/00064 Refer\u00e8ncia: PMP22\/00083 <\/p>\n <\/p>\n L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Dues investigadores de l’IDIBELL lideraran projectes de recerca multic\u00e8ntrics en medicina personalitzada de precisi\u00f3: PRECISION-ILD, liderat per la Dra. Maria Molina (IDIBELL i Hospital Universitari de Bellvitge) i IMPaCT_VUSCan, liderat per la Dra. Conxi L\u00e1zaro (IDIBELL i Institut Catal\u00e0 d’Oncologia). Els dos projectes s\u00f3n multic\u00e8ntrics i estan finan\u00e7ats pels fons Next Generation EU dins d’una convocat\u00f2ria especial de l\u2019ISCIII sobre medicina personalitzada.<\/p>\n","protected":false},"author":8,"featured_media":22844,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,417,334,466,447,467],"tags":[],"class_list":["post-22843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-hereditari-noticies","category-medicina-translacional","category-p-de-malalties-cardiovasculars-respiratories-sistemiques-i-denvelliment-cellular","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-pneumologia"],"publishpress_future_action":{"enabled":false,"date":"2025-01-25 00:45:30","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22843"}],"version-history":[{"count":6,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22843\/revisions"}],"predecessor-version":[{"id":26677,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22843\/revisions\/26677"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22844"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/02\/thumbnail_image002.png\")
<\/p>\n
\nT\u00edtol: Gen\u00f3mica funcional: desarrollo e implementaci\u00f3n de una plataforma para el estudio de casos de c\u00e1ncer hereditario sin resolver
\nInvestigador Principal: Conxi L\u00e1zaro Garc\u00eda
\nImport finan\u00e7able: 3.179.990,00 \u20ac<\/p>\n
\nT\u00edtol: Integraci\u00f3n de las caracter\u00edsticas moleculares, gen\u00f3micas, morfol\u00f3gicas, y ambientales para mejorar el diagn\u00f3stico y tratamiento de precisi\u00f3n en Enfermedades Pulmonares Intersticiales Difusas fibrosantes (Precision-EPID)
\nInvestigador Principal: Mar\u00eda Molina Molina
\nImport finan\u00e7able: 3.049.970,00 \u20ac<\/p>\n